NASDAQ
No price data available for this timeframe.
Aclaris Therapeutics, Inc. (ACRS) has a free cash flow growth of -37.96% as of Friday, May 29, 2026. This represents a 334.33% decrease compared to its 12-month average of 16.20%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.